Patent 7998971 was granted and assigned to BrainCells on August, 2011 by the United States Patent and Trademark Office.
The instant disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system. The disclosure includes compositions and methods based on use of a 4-acylaminopyridine derivative in combination with one or more other neurogenic agents. One 4-acylaminopyridine derivative is MKC-231.